Misonix announces new HIFU distribution agreement for Portugal

164

Sonablate is a state of the art High Intensity Focused Ultrasound (HIFU) instrument used for the trans-rectal ablation of tumours of the prostate gland.

Misonix, a developer of minimally invasive ultrasonic medical device technology, which is used in Europe for the ablation of tumours, and worldwide for other acute health conditions, has entered into a definitive, 5-year distribution agreement with Ekrior Lda, a division of Avanco Sistemas Medicos, based in Barcarena, Portugal. The agreement expands on and replaces a previous agreement with Avanco.


Under the terms of the agreement, Ekrior will market the Sonablate 500 High Intensity Focused Ultrasound (HIFU) System as a mobile, “fee for use” service to hospitals throughout Portugal. Misonix and Ekrior will share the “fee for use” revenue for the length of the agreement plus any extension periods. Procedure minimums for “fee per use” revenue are part of the agreement.


Ekrior management, drawing on Avanco’s long and successful history of introducing state of the art medical products and services, with an emphasis on urology and oncology, presents an excellent opportunity for rapid expansion in the Portuguese market.


Sonablate is a state of the art HIFU instrument used for the trans-rectal ablation of tumours of the prostate gland. Characteristics of HIFU, when used for this purpose, are clinical outcomes similar to other treatment modalities, but with low instances of urinary incontinence and sexual impotence.